246 related articles for article (PubMed ID: 34090452)
1. Feasibility and outcomes of cytoreductive surgery and HIPEC for peritoneal surface malignancies in low- and middle-income countries: a single-center experience of 232 cases.
Deo S; Ray M; Bansal B; Bhoriwal S; Bhatnagar S; Garg R; Gupta N; Sharma A; Kumar L; Thulkar S; Dhamija E; Mathur S; Das P
World J Surg Oncol; 2021 Jun; 19(1):164. PubMed ID: 34090452
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
3. The role of cytoreductive surgery and HIPEC for the treatment of primary and secondary peritoneal malignancies-experience from a tertiary care center in Germany.
Reese M; Eichelmann AK; Nowacki TM; Pascher A; Sporn JC
Langenbecks Arch Surg; 2024 Apr; 409(1):113. PubMed ID: 38589714
[TBL] [Abstract][Full Text] [Related]
4. Learning Curve of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy - an Analysis of Critical Perioperative and Surgical Outcomes among 155 Peritoneal Surface Malignancy Patients Treated at a Tertiary Care Cancer Centre.
Saikia J; Deo S; Ray M; Mishra A; Bansal B; Bhoriwal S; Bhatnagar S; Mishra S; Bharti SJ; Kumar V; Kumar M
Clin Oncol (R Coll Radiol); 2022 Jul; 34(7):e305-e311. PubMed ID: 35379523
[TBL] [Abstract][Full Text] [Related]
5. Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
Somashekhar SP; Yethadka R; Kumar C R; Ashwin KR; Zaveri S; Rauthan A
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):577-581. PubMed ID: 31677939
[TBL] [Abstract][Full Text] [Related]
6. Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25-year experience.
Nikiforchin A; Gushchin V; King MC; Baron E; Nieroda C; Sittig M; Sardi A
J Surg Oncol; 2021 Mar; 123(4):1030-1044. PubMed ID: 33524164
[TBL] [Abstract][Full Text] [Related]
7. Pelvic exenteration, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy: experience and outcomes from an exenterative and peritonectomy unit.
Flood MP; Waters PS; Soucisse M; Ramsay R; Michael M; McCormick JJ; Warrier S; Heriot A
Langenbecks Arch Surg; 2021 Dec; 406(8):2807-2815. PubMed ID: 34495403
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
[TBL] [Abstract][Full Text] [Related]
9. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.
Azzam AZ; Alyahya ZA; Wusaibie AAA; Amin TM
Indian J Gastroenterol; 2017 Nov; 36(6):452-458. PubMed ID: 29185227
[TBL] [Abstract][Full Text] [Related]
11. Re-do cytoreductive surgery for peritoneal surface malignancy: Is it worthwhile?
Narasimhan V; Cheung F; Waters P; Peacock O; Warrier S; Lynch C; Michael M; Ramsay R; Heriot A
Surgeon; 2020 Oct; 18(5):287-294. PubMed ID: 31848069
[TBL] [Abstract][Full Text] [Related]
12. Surgical Options for Peritoneal Surface Metastases from Digestive Malignancies-A Comprehensive Review.
Eftimie MA; Potlog G; Alexandrescu ST
Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837456
[TBL] [Abstract][Full Text] [Related]
13. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.
Vaira M; Robella M; Mellano A; Sottile A; De Simone M
Int J Hyperthermia; 2014 Dec; 30(8):565-9. PubMed ID: 25430988
[TBL] [Abstract][Full Text] [Related]
14. Laparoscopic cytoreductive surgery and HIPEC in LAMN with small volume of peritoneal disease: a valuable option of treatment for good patient-related experience measures (PREMs).
Cusumano C; Carrere S; Bouillin A; Nougaret S; Khellaf L; Quénet F; Sgarbura O
Surg Endosc; 2022 Jul; 36(7):4757-4763. PubMed ID: 34845545
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases.
Narasimhan V; Das A; Warrier S; Lynch C; McCormick J; Tie J; Michael M; Ramsay R; Heriot A
Langenbecks Arch Surg; 2019 Aug; 404(5):527-539. PubMed ID: 31377856
[TBL] [Abstract][Full Text] [Related]
16. Initial Experience of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Baltic Country Center.
Račkauskas R; Baušys A; Jurgaitis J; Paškonis M; Strupas K
J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233421
[No Abstract] [Full Text] [Related]
17. Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies.
Passot G; Bakrin N; Isaac S; Decullier E; Gilly FN; Glehen O; Cotte E
Eur J Surg Oncol; 2014 Aug; 40(8):957-62. PubMed ID: 24209429
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive Surgery with Hyperthermic Intrathoracic Chemotherapy for Patients with Intrapleural Dissemination of Peritoneal Surface Malignancies.
Nikiforchin A; Gushchin V; King MC; Baron E; Lopez-Ramirez F; Sardi A
Ann Surg Oncol; 2021 Dec; 28(13):9126-9135. PubMed ID: 34263367
[TBL] [Abstract][Full Text] [Related]
19. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
[TBL] [Abstract][Full Text] [Related]
20. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
